Contact
News
Stock Info
Governance
Financials & Filings
Resources

*

Stock

Stock info

icon

Upcoming Events

January 14, 2025 at 2:15 PM PST
43rd Annual J.P. Morgan Healthcare Conference
Add to Outlook
Add to Google Calendar
Listen to Webcast
February 13, 2025 at 8:30 AM EST
GE HealthCare Fourth Quarter and Full Year 2024 Earnings Conference Call
Add to Outlook
Add to Google Calendar
Listen to webcast
Show all

GE HealthCare Third Quarter 2024 Earnings Conference Call

Webcast
Presentation 723.4 KB
Press Release 1 MB
Earnings Supplemental Info 99.8 KB

Sustainability Report

GE HealthCare’s 2023 Sustainability Report

Sustainability Report

View all events

>$1bn

annual R&D spend in 2023

1bn+

patients served annually

4m+

units installed across the globe

$19.6bn

revenue in 2023

News & events

Stay up to date with GE HealthCare's latest investor news and events

December 12, 2024

GE HealthCare to announce fourth quarter and full year 2024 results on February 13, 2025

News Release arrow-icon

December 5, 2024

GE HealthCare Expands Its Effortless Recon DL Portfolio, Bringing Advanced Deep Learning Image Reconstruction to Clinicians Worldwide

News Release arrow-icon

December 4, 2024

GE HealthCare showcases commitment to sustainable innovation at RSNA 2024

News Release arrow-icon

February 13, 2025 at 8:30 AM EST
GE HealthCare Fourth Quarter and Full Year 2024 Earnings Conference Call
Add to Outlook
Add to Google Calendar
Listen to webcast
January 14, 2025 at 2:15 PM PST
43rd Annual J.P. Morgan Healthcare Conference
Add to Outlook
Add to Google Calendar
Listen to Webcast
December 10, 2024 at 11:00 AM GMT
Nasdaq Investor Conference
Listen to webcast
More information is coming soon.

A message from the President & CEO of Pharmaceutical Diagnostics

Kevin ONeil
quote-icon

GE HealthCare is committed to innovating and investing to shape the future of molecular imaging, increasing diagnostic confidence and addressing unmet patient needs. We're particularly excited about Flyrcado, the first and only FDA-approved F18 PET myocardial perfusion imaging tracer for the detection of coronary artery disease, and we see significant advancements and opportunities to drive more personalized care in the space.”

Kevin O’Neill, President & CEO of Pharmaceutical Diagnostics, GE HealthCare

Quick Links

SEC Filings

FAQs

Contacts

Institutional and fixed income investors

Carolynne Borders, Investor relations

carolynne.borders@gehealthcare.com

Attn: Investor relations

GE HealthCare

500 West Monroe Street

Chicago, IL 60661

Retail investors

Erin Sekula, Investor relations

erin.sekula@gehealthcare.com

Attn: Investor relations

GE HealthCare

500 West Monroe Street

Chicago, IL 60661

Transfer agent

Equiniti Trust Company

www.shareowneronline.com

+1-833-914-2122 (toll free)

+1-651-450-4064 (international number)

GE HealthCare Investor Relations

investor@gehealthcare.com

833-735-1139

Stay connected with investor news

ge-icon

Investor Relations

GEHealthcare.com

© 2024 GE HealthCare

Cookies
Careers
Compliance
Privacy